539 related articles for article (PubMed ID: 21810444)
1. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.
Armentero MT; Pinna A; Ferré S; Lanciego JL; Müller CE; Franco R
Pharmacol Ther; 2011 Dec; 132(3):280-99. PubMed ID: 21810444
[TBL] [Abstract][Full Text] [Related]
2. L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
Bonaventura J; Rico AJ; Moreno E; Sierra S; Sánchez M; Luquin N; Farré D; Müller CE; Martínez-Pinilla E; Cortés A; Mallol J; Armentero MT; Pinna A; Canela EI; Lluís C; McCormick PJ; Lanciego JL; Casadó V; Franco R
Neuropharmacology; 2014 Apr; 79():90-100. PubMed ID: 24230991
[TBL] [Abstract][Full Text] [Related]
3. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.
Simola N; Morelli M; Pinna A
Curr Pharm Des; 2008; 14(15):1475-89. PubMed ID: 18537671
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment.
Beggiato S; Antonelli T; Tomasini MC; Borelli AC; Agnati LF; Tanganelli S; Fuxe K; Ferraro L
Curr Protein Pept Sci; 2014; 15(7):673-80. PubMed ID: 25175458
[TBL] [Abstract][Full Text] [Related]
5. An update on adenosine A2A receptors as drug target in Parkinson's disease.
Vallano A; Fernandez-Duenas V; Pedros C; Arnau JM; Ciruela F
CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):659-69. PubMed ID: 21838670
[TBL] [Abstract][Full Text] [Related]
6. Purinergic signaling in Parkinson's disease. Relevance for treatment.
Navarro G; Borroto-Escuela DO; Fuxe K; Franco R
Neuropharmacology; 2016 May; 104():161-8. PubMed ID: 26211977
[TBL] [Abstract][Full Text] [Related]
7. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
[TBL] [Abstract][Full Text] [Related]
8. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
[TBL] [Abstract][Full Text] [Related]
9. Allosteric Interactions between Adenosine A
Prasad K; de Vries EFJ; Elsinga PH; Dierckx RAJO; van Waarde A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572077
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers.
Soriano A; Ventura R; Molero A; Hoen R; Casadó V; Cortés A; Fanelli F; Albericio F; Lluís C; Franco R; Royo M
J Med Chem; 2009 Sep; 52(18):5590-602. PubMed ID: 19711895
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
Kulisevsky J; Poyurovsky M
Eur Neurol; 2012; 67(1):4-11. PubMed ID: 22134373
[TBL] [Abstract][Full Text] [Related]
12. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
Tanganelli S; Sandager Nielsen K; Ferraro L; Antonelli T; Kehr J; Franco R; Ferré S; Agnati LF; Fuxe K; Scheel-Krüger J
Parkinsonism Relat Disord; 2004 Jul; 10(5):273-80. PubMed ID: 15196505
[TBL] [Abstract][Full Text] [Related]
13. The dopamine D2 and adenosine A2A receptors: past, present and future trends for the treatment of Parkinson's disease.
Jorg M; Scammells PJ; Capuano B
Curr Med Chem; 2014; 21(27):3188-210. PubMed ID: 24533801
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum.
Orrú M; Quiroz C; Guitart X; Ferré S
Neuropharmacology; 2011; 61(5-6):967-74. PubMed ID: 21752341
[TBL] [Abstract][Full Text] [Related]
15. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological interactions between adenosine A
Pinna A; Serra M; Marongiu J; Morelli M
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S37-S44. PubMed ID: 33349579
[TBL] [Abstract][Full Text] [Related]
17. Behavioral control by striatal adenosine A
Taura J; Valle-León M; Sahlholm K; Watanabe M; Van Craenenbroeck K; Fernández-Dueñas V; Ferré S; Ciruela F
Genes Brain Behav; 2018 Apr; 17(4):e12432. PubMed ID: 29053217
[TBL] [Abstract][Full Text] [Related]
18. Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer.
Ferré S; Bonaventura J; Tomasi D; Navarro G; Moreno E; Cortés A; Lluís C; Casadó V; Volkow ND
Neuropharmacology; 2016 May; 104():154-60. PubMed ID: 26051403
[TBL] [Abstract][Full Text] [Related]
19. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Chen JF
Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
[TBL] [Abstract][Full Text] [Related]
20. Adenosine A2A antagonists in Parkinson's disease: what's next?
Hickey P; Stacy M
Curr Neurol Neurosci Rep; 2012 Aug; 12(4):376-85. PubMed ID: 22585137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
